LYNBROOK, N.Y., June 3 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (OTC Bulletin Board: BSTC.OB) today announced that it sold 100,000 unregistered shares of its common stock priced at $13 per share with aggregate proceeds to BioSpecifics of $1,300,000. The shares were purchased by an investment group on May 30, 2008. The shares were sold in a company managed PIPE transaction at a premium over the market price.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has
developed and licensed injectable collagenase for three clinical
indications. It has a development and licensing agreement with Auxilium
Pharmaceuticals, Inc. for clinical indications in Dupuytren's disease,
Peyronie's disease and frozen shoulder (adhesive capsulitis).
BioSpecifics' main website is at
its Dupuytren's Disease patient discussion forum at
and its Peyronie's Disease patient discussion forum at
|SOURCE BioSpecifics Technologies Corp.|
Copyright©2008 PR Newswire.
All rights reserved